Navigation Links
PharmAthene Reports First Quarter 2012 Financial Results
Date:5/8/2012

s payable$

1,410,516$

1,445,700Accrued expenses and other liabilities2,850,0723,169,642Current portion of long term debt195,412-Short term debt857,808-Total current liabilities5,313,8084,615,342Other long term liabilities555,983449,709Long term debt, less current portion2,234,712-Derivative instruments2,878,3141,886,652Total liabilities10,982,8176,951,703Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized;
48,314,510 and 48,236,172 shares issued and outstanding at March 31, 2012
and December 31, 2011, respectively4,8324,824Additional paid-in-capital209,111,489208,525,917Accumulated other comprehensive income1,023,8911,010,522Accumulated deficit(196,369,345)(193,689,457)Total stockholders'
equity13,770,86715,851,806Total liabilities and stockholders' equity$

24,753,684$

22,803,509 PHARMATHENE, INC. 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree months ended March 31,20122011Revenue

$

6,149,052$

6,337,722Operating expenses:Research and development4,705,3575,820,374General and administrative2,948,4814,939,654Depreciation and amortization85,910117,629Total operating expenses7,739,74810,877,657Loss from operations(1,590,696)(4,539,935)Other income (expense):Interest income2,9883,154Interest expense(3,028)(15,435)Other income (expense)52,915(11,906)Change in fair value of derivative instruments(991,662)2,488,465Total other income (expense)(938,787)2,464,278Net loss before income taxes(2,529,483)(2,075,657) Income tax expense(150,405)- Net loss

$

(2,679,888)$

(2,075,657)Basic and diluted net loss per share

$

(0.06)$

(0.04)Weighted average shares used in calculation of
basic and diluted net loss per share48,269,89446,276,874 


'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
2. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
3. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
4. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
5. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
6. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
9. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
10. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... SUNNYVALE, Calif., June 1 Pharmacyclics, Inc. (Nasdaq: ... on Form S-3 with the Securities and Exchange Commission (the ... The rights offering will be made through the distribution of ... stock, par value $0.0001 per share, at a subscription price ...
... ... Generation nonfood Biofuel crops Knowledge Platform ,CJP,s "3rd Global Jatropha Hi-Tech ... all set to provide the most authoritative Knowledge platform for Development ... Priorities to Feed Biodiesel Industry Worldwide. The biodiesel industry has met ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Pharmacyclics Files Registration Statement for Rights Offering 2Pharmacyclics Files Registration Statement for Rights Offering 3Pharmacyclics Files Registration Statement for Rights Offering 4Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 2Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 3Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... ago that many genes likely influence how tall a person ... the myriad genes. Now an international research team brings light ... with human height the first consistent genetic link to ... advance online edition of Nature Genetics, stem from a large-scale ...
... Mass. -- Biologists at Harvard University have identified the ancient ... of orchids in the fossil record, a find they say ... Their analysis, published this week in the journal Nature, ... much longer ago than many scientists had estimated. The extinct ...
... (August 30, 2007) Saudi Arabias King Abdullah University ... Institute of Technology, Bombay (IIT Bombay) , signed ... to work together to foster world-class programs that will ... fundamental and applied chemical sciences for the benefit of ...
Cached Biology News:Genome study shines light on genetic link to height 2Genome study shines light on genetic link to height 3First orchid fossil puts showy blooms at some 80 million years old 2First orchid fossil puts showy blooms at some 80 million years old 3Saudi Arabia's KAUST and IIT, Bombay to Collaborate on Scientific Research 2
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
...
... clone 41D GenBank Accession Number ... clusterin purified from human serum Formulation: ... and 0.05% sodium azide Quality Assurance: ... HeLa cells or MCF-7 cell lysates. ...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: